CTIS2023-506033-29-00进行中（未招募）1 期
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer - 61186372NSC3001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 308
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous NSCLC with documented primary EGFR Exon 20ins activating mutation (a copy of the mutation analysis must be submitted during screening) performed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (US sites) or an accredited (outside of the US) local laboratory., Participant must have measurable disease according to RECIST v1.1. If only one measurable lesion exists, it may be used for the screening biopsy (if required for submission of tumor tissue) if the baseline tumor assessment scans are performed =14 days after the biopsy., Participant must have ECOG performance status 0 or 1., Participant must have adequate organ and bone marrow function as follows, without history of red blood cell transfusion or platelet transfusion within 7 days prior to the date of the laboratory test. - Hemoglobin =10 g/dL - Absolute neutrophil count =1.5?109/L, without use of granulocyte colonystimulating factor (G-CSF) within 10 days prior to the date of the test - Platelets =100?109/L - ALT and aspartate aminotransferase (AST) =3×upper limit of normal (ULN) - Total bilirubin =1.5?ULN (participants with Gilbert’s syndrome can enroll if conjugated bilirubin is within normal limits) - Creatinine clearance >50 mL/min as measured or calculated by Cockcroft-Gault formula
排除标准
- •Participant has received any prior systemic treatment for locally advanced or metastatic disease, with the following exceptions: - Prior adjuvant or neoadjuvant platinum-based doublet chemotherapy is allowed, if completed at least 12 months prior to signing the study ICF. - Localized radiotherapy to the lung must be completed at least 6 months prior to randomization. Palliative radiation to other sites must be completed at least 7 days prior to randomization. - Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as non-standard first-line therapy for the treatment of locally advanced or metastatic disease is allowed, if: 1) treatment duration did not exceed 8 weeks; 2) lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography [CT] report showing increase in tumor burden from baseline should be submitted); 3) associated toxicities have resolved to baseline; and 4) the EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer. Prior therapy with investigational EGFR TKI agents targeting Exon 20ins mutations, including TAK788 or poziotinib, is not allowed., Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)., Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization is eligible). If brain metastases are diagnosed on Screening imaging, the participant may be rescreened for eligibility after definitive treatment., Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation., Participant has a medical history of ILD, including drug-induced ILD, or radiation pneumonitis., Participant has a history of clinically significant cardiovascular disease including, but not limited to: - Diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to randomization or any of the following within 6 months prior to randomization: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary. - Prolonged corrected QT interval by Fridericia’s (QTcF) >480 msec, clinically significant cardiac arrhythmia, or electrophysiologic disease (eg, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate) - Uncontrolled (persistent) hypertension: systolic blood pressure >160 mm Hg; diastolic blood pressure >100 mm Hg - Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of study Day 1 (refer to Appendix 6: New York Heart Association Criteria) - Pericarditis/clinically significant pericardial effusion - Myocarditis - Baseline left ventricular ejection fraction below the lower limit of normal as assessed by screening echocardiogram (ECHO) or multigated acquisition scan., Participant has an uncontrolled illness, including but not limited to the following: - Diabetes - Ongoing or active bacterial infection (includes infection requiring treatment with antimic
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000633-40-DEJanssen-Cilag International NV300
进行中（未招募）
1 期
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000633-40-PTJanssen-Cilag International NV300
进行中（未招募）
1 期
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000633-40-FRJanssen-Cilag International NV300
进行中（未招募）
1 期
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000633-40-ITJANSSEN CILAG INTERNATIONAL NV300
进行中（未招募）
1 期
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2020-000633-40-PLJanssen-Cilag International NV300